Author + information
- S1936879815022189-e58cbeb7894da67897e27b3669a57da7Tomo Ando1,
- S1936879815022189-743cdbbf7ef26363e6a149ce88e6ef09David Slovut2 and
- S1936879815022189-f26a03337d76cf693d66385cf2d053ecCynthia Taub2
Transcathether aortic valve replacement (TAVR) is expected to have shorter hospitalization period than surgical aortic valve replacement. However, there may be factors associated with longer hospital stay (LOS). We aimed to assess factors, causes and impact of LOS after TAVR.
Medical records of 110 patients who had TAVR at a single center were retrospectively reviewed. Hospital stay was defined as the duration from the time the patients had TAVR to discharge date. LOS was defined as hospital stay more than seven days. Patients who had procedure related complications or in hospital death were excluded.
One hundred and two patients were finally included in the study. Mean age was 82±8 years old (Male, 49%). Median hospital stay day was 5 (3-7) days. The primary endpoint occurred in 33 patients. On multivariate logistic regression analysis, after adjusted for age, diabetes on insulin therapy (DMIT), cases performed one year later and access, DMIT (OR 4.49 95% CI 1.39-14.5, p=0.012) and surgical access (OR 3.48 95% CI 1.40-8.63, p=0.012) remained as the predictors for LOS. After adjusted for other complications, antibiotics therapy (OR 10.3, 95% CI 2.80-37.7, p<0.001) and post TAVR AF (OR 12.3, 95%CI 2.93-51.3, p<0.001) remained major causes for LOS. During median of 123 days (range 2-896 days), there was no difference in mortality rate (Log rank, p=0.23). Also, there was no difference in 30 days re-admission rate (p=0.20).
Our study demonstrated that DMIT and surgical access was an independent predictor for longer hospital stay after TAVR. Major causes for LOS were infectious disease requiring antibiotics therapy and post TAVR AF. However, it did not affect the 30 days re-admission rate or the mid-term mortality.